Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + Pembrolizumab in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT07744126Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Countries
- 3
01
Overview
A Phase 2 trial of telisotuzumab adizutecan in head and neck squamous cell carcinoma (HNSCC), sponsored by AbbVie Inc.. Started Sep 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07744126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744126.